|TRV027 (AT1R)||Acute Heart Failure||- Phase 2|
|TRV130 (MOR)||Post-Operative Pain||- Phase 1|
|TRV734 (MOR)||Moderate-to-Severe Pain||- Preclinical|
|Delta Opioid||Pain, Parkinson's disease||- Lead Optimization|
|Kappa Opioid||Neuropathic Pain||- Lead Optimization|
TRV130 is an intravenous G protein biased ligand that targets the mu opioid receptor. Trevena is developing TRV130 for the treatment of moderate-to-severe acute pain where intravenous therapy is needed, with a clinical development focus in acute postoperative pain.
Copyright © Trevena, Inc.